GORDON CARL L (CIK 1282930) reported 15 SEC Form 4 insider transactions across 5 companies over the past 18 months (most recent 2026-09-23). Recent activity: Buy ETRA (2.0M shares), Buy ETRA (1.1M shares), Buy ETRA (1.7M shares), Buy ETRA (333,333 shares), Buy ETRA (758,279 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 2.0M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.1M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.7M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 333,333 | $5.0M |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 758,279 | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.0M | $15.0M |
| 2026-08-12 | BlossomHill Therapeutics, Inc. (BLSM) | Director | Buy | 1.0M | $0 |
| 2026-08-12 | BlossomHill Therapeutics, Inc. (BLSM) | Director | Buy | 1.0M | $0 |
| 2026-08-12 | BlossomHill Therapeutics, Inc. (BLSM) | Director | Buy | 625,000 | $10.0M |
| 2026-07-29 | Scribe Therapeutics, Inc. (SCTX) | Director | Buy | 348,825 | $0 |
| 2026-07-29 | Scribe Therapeutics, Inc. (SCTX) | Director | Buy | 1.0M | $15.0M |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 140,057 | $2.5M |
| 2025-12-18 | Keros Therapeutics, Inc. (KROS) | Director | Sell | 74,465 | $1.3M |
| 2025-06-06 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 5,250 | $0 |
| 2025-04-11 | Compass Therapeutics, Inc. (CMPX) | Director | Sell | 3.6M | $5.7M |
来源：SEC Form 4 申报文件 · 截至 2026-09-23